Generics Bulletin Editor’s Picks For Q1 2022
Highlights Across The Off-Patent Sector From January To March 2022
Executive Summary
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.